Whirly lollipop on orange background.

Neothetics (NEOT) is on the road now to fund the continued development of their injection-based approach to fat loss.  It's a smallish deal of 4.3M shares with a $13-15 price range. Three mid-market banks: Piper Jaffray, Guggenheim and Needham are on the cover. Post-IPO there will be ~14M shares outstanding for a market capitalization of ~$200M at the mid-point of the range. [A transcript of the IPO roadshow is in process but the NEOT IPO roadshow slides are available.]

Neothetics aims at the midsection of "thin people . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!